Patients and clinicians face tough choices when standard schizophrenia treatments don’t bring relief. Pharmaceutical treatments have advanced over decades, but 30% of people with schizophrenia still experience symptoms that don’t respond well to conventional approaches. Treatment resistance remains the biggest problem in psychiatric care today. Surgical interventions have emerged as alternatives to think over for patients who’ve tried all first-line treatments. Antipsychotic medications are still the foundations of schizophrenia treatment protocols. The latest research suggests that targeted surgical procedures might offer hope for specific patient groups. These interventions—including Deep Brain Stimulation (DBS), Transcranial Magnetic Stimulation (TMS), and experimental approaches—mark a major shift from traditional management strategies. Schizophrenia treatment’s history shows a steady development from institutional confinement to community-based care. Psychosocial supports now work alongside pharmacological approaches. We have a long way to go, but we can build on this progress. Patients with treatment-resistant forms of the disorder often experience lower quality of life and major functional impairment, even when they follow first-line treatment recommendations. This piece gets into the evidence that compares surgical and traditional approaches for managing schizophrenia symptoms and treatment outcomes. We want to provide a complete overview of current treatment options and how well they work by analyzing clinical trial data, neuroimaging findings, and patient-reported experiences. It also explores the factors that should guide shared decision-making between patients and their healthcare providers as they evaluate these interventions.
Myszkowska et al. (2025) studied this question.